(Q33348049)

26 July 2017

1 reference

title

Heparin-induced thrombocytopenia: pathogenesis and management (English)

1 reference

26 July 2017

Heparin‐induced thrombocytopenia: pathogenesis and management (English)

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

3 January 2024

0 references

1 reference

heparin-induced thrombocytopenia

1 reference

1

Theodore E Warkentin

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

full work available at URL

26 July 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2141.2003.04334.x

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2141.2003.04334.x

3 January 2024

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

British Journal of Haematology

3 January 2024

published in

1 reference

26 July 2017

volume

121

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

535-555

1 reference

Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Identification of T cells responding to a self-protein modified by an external agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Heparin-induced thrombocytopenia is rare in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Intraoperative heparin flushes and subsequent acute heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Very low platelet counts in post-transfusion purpura falsely diagnosed as heparin-induced thrombocytopenia. Report of four cases and review of literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Rapid detection of heparin-induced platelet antibodies with particle gel immunoassay (ID-HPF4)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Further characterization of antibody and antigen in heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Delayed-onset heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Heparin-induced thrombocytopenia in pediatrics

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

A 14-year study of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Delayed-onset heparin-induced thrombocytopenia and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Temporal aspects of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Off-pump coronary artery bypass grafting for acute heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04334.X

Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia

21 January 2018

3

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia.

3 January 2024

6

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation

3 January 2024

7

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

Heparin-induced thrombocytopenia and antithrombotic therapy

3 January 2024

12

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

Activation of platelets by sera containing IgG1 heparin-dependent antibodies: an explanation for the predominance of the Fc gammaRIIa "low responder" (his131) gene in patients with heparin-induced thrombocytopenia

3 January 2024

18

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

Pentosan-induced thrombocytopenia: support for an immune complex mechanism

3 January 2024

29

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

Antigen Generation in Heparin-Associated Thrombocytopenia: The Nonimmunologic Type and the Immunologic Type Are Closely Linked in Their Pathogenesis

3 January 2024

30

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

Heparin-associated thrombocytopenia in a patient treated with polysulphated chondroitin sulphate: evidence for immunological crossreactivity between heparin and polysulphated glycosaminoglycan

3 January 2024

33

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

Heparin-associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides

3 January 2024

34

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

Rapid induction of hepatocyte growth factor by heparin

3 January 2024

41

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia

3 January 2024

43

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

Simultaneous binding of heparin and platelet factor-4 to platelets: further insights into the mechanism of heparin-induced thrombocytopenia

3 January 2024

44

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban

3 January 2024

46

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin

3 January 2024

61

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

Pseudopulmonary embolism: acute respiratory distress in the syndrome of heparin-induced thrombocytopenia

3 January 2024

73

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia

3 January 2024

84

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

Characterization of the humoral immune response in heparin-induced thrombocytopenia

3 January 2024

85

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells

3 January 2024

88

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

Heparin-induced skin lesions

3 January 2024

91

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocyto

3 January 2024

92

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin

3 January 2024

103

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

Heparin-induced thrombocytopenia and cardiac surgery

3 January 2024

105

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

Transient global amnesia associated with acute heparin-induced thrombocytopenia

3 January 2024

114

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients

3 January 2024

121

1 reference

https://api.crossref.org/works/10.1046/J.1365-2141.2003.04334.X

3 January 2024

Identifiers

1 reference

26 July 2017

1 reference